Pluri Inc., a leading biotechnology company, has recently been granted a new U.S. patent for its unique method of expanding immune cells using proprietary technology. The company’s 3D cell expansion technology is designed to replicate the natural environment in the human body where immune cells are found in lymph nodes. Through a closely monitored and fully automated bioreactor system, cells are provided with the necessary conditions for expansion, resulting in a scalable and high-quality process.
Pluri’s patented technology addresses the key challenges faced by existing allogeneic cell therapies, such as donor cell availability and scalability issues. By ensuring that immune cells retain their functionality, integrity, and therapeutic efficacy during expansion, this method offers a promising solution to the growing demand for advanced cell-based therapies for immune disorders and neurodegenerative diseases. This innovation has the potential to unlock new opportunities for therapeutic advancements and commercial success in the field of cell therapy.
As CEO and President of Pluri Inc., Yaky Yanay expressed his excitement about the milestone: “We are dedicated to developing cutting-edge medical treatments through our commitment to technology and decades of experience,” he said. “The patented technology represents a significant advancement in immune cell expansion, meeting the rising global demand for advanced cell-based therapies.” Yanay added that Pluri’s dedication to advancing cell therapies goes beyond just research and development; it also includes manufacturing services through its new business division, PluriCDMO. This expansion into manufacturing services further establishes Pluri’s commitment to advancing cell therapies and serving patients worldwide who need innovative treatments.
:max_bytes(150000):strip_icc()/GettyImages-1240824101-66e3a7a74e7645d4837edb8ac684df31.jpg)
